All-time high valuations offer biopharma companies a window of opportunity to re-assess their portfolio and refocus their business, raise capital and create shareholder value by divesting their non-core assets to fuel innovation. These divested assets will create innovation opportunities for smaller biotechs to pivot the clinical strategy for further indications. Panelists investigated whether life sciences companies are sufficiently using divestitures as a corporate finance tool to improve capital efficiency and create shareholder value. They found that companies which strategically divested assets were in fact twice as efficient in capital utilization, and also increased shareholder value by 20% when compared to similar companies which did not divest any assets within the same period. Attendees will hear the numerical research findings as well as real-world examples articulated by operating executives discussing best divestment practices.